Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma

NCT06698692 · tracked via the Priya Life Science China tracker

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Phase

Observational

Started

2024-04-02

Last updated

2024-11-21

Condition(s) studied

ESCC

Investigational drug(s) / intervention(s)

Trilaciclib Injection [Cosela]

Trilaciclib Injection [Cosela]: Trilaciclib Combined chemoradiotherapy

Study summary

Clinical data of patients with synchronous radiotherapy for esophageal cancer in the Department of Radiology of Jiangsu Provincial People's Hospital were collected. Patients were divided into trilaciclib group (34 cases) and control group (169 cases) based on whether trilaciclib was used or not. Patients in the trilaciclib group were given trilaciclib before each chemotherapy treatment. Propensity score matching (PSM) was used to balance the baseline characteristics between the two groups on a 1:1 ratio. After pairing, the rates of bone marrow suppression and other adverse events were compared between the two groups.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * age ≥18 years; * pathological diagnosis of esophageal squamous cell carcinoma; * failure to undergo surgical treatment; * completion of definitive chemoradiotherapy or chemoradiotherapy combined with immunotherapy. Exclusion Criteria: * history of other malignant tumors; * difficulty in follow-up; * insufficient clinical information.

Primary outcome measure(s)

Incidence of grade ≥3 neutropenia — during Trilaciclib plus chemotherapy assessed up to 1 years
Incidence of grade ≥3 neutropenia

Trial sites (1)

Facility	City	Region	Status
The First Affiliated Hospital of Nanjing Medical University	Nanjing	Jiangsu	Recruiting

More The First Affiliated Hospital with Nanjing Medical University trials in China

CPVI With Modified Linear Ablation Versus CPVI in Patients With Long-standing Persistent Atrial Fibrillation (SINUS) Recruiting

Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib Recruiting

A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11 Recruiting

Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer Starting soon

Ultrasound-Enhanced Delivery of Compound TXA Solution in Melasma Recruiting

Other trials for the same condition

SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy Starting soon

TAS-102 Plus Radiotherapy in Elderly ESCC Starting soon

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors Recruiting

Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2 Starting soon

Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06698692 on ClinicalTrials.gov ↗ ← All trials in China